Logo

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Share this

Novartis' Xolair (omalizumab) Receives EU's Approval for Severe Allergic Asthma (SAA) and Chronic Spontaneous Urticaria (CSU)

Shots:

  • The approval is based on trial results assessing Xolair IV (q2w or q4w) in 1M patients with SAA and CSU for 13 years
  • The study demonstrated in reduction of severe exacerbations- corticosteroid use in SAA patients and reduction in symptoms of CSU with safe and well-tolerated results
  • Xolair (omalizumab) is a prefilled syringe (PFS) self-administered syringe- used for targeting  IgE and is approved by EU and the US FSA for moderate-to-severe or severe persistent allergic asthma in 2005 & 2003 respectively

Ref: Novartis | Image: Novartis


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions